Latest news with #cognitiveperformance
Yahoo
30-07-2025
- Business
- Yahoo
BFCH Unveils Business Plan and Platform Vision Following Leadership Transition and Structural Reset
CRESTVIEW, FL - July 30, 2025 (NEWMEDIAWIRE) - BitFrontier Capital Holdings, Inc. (OTC: BFCH), doing business as EVERMIND Holdings, Inc., today announced the publication of its updated strategic business plan following a recent change in control, leadership transition, and material restructuring of its capital base. On July 21, 2025, physician-entrepreneur Dr. Jordan P. Balencic was appointed Chief Executive Officer following a formal change of control and board resolution. As the Company's new controlling shareholder and CEO, Dr. Balencic brings a long-term ownership mindset and has moved quickly to realign BFCH's corporate strategy, strengthen its financial position, and begin rebuilding trust with the Company's investor base. The roadmap ahead centers on transforming BFCH into a restructured public platform focused on human optimization, cognitive performance, and longevity infrastructure. "In just one week, we've made meaningful progress in resetting the structure of the Company," said Dr. Balencic. "The newly released business plan outlines our preliminary roadmap and current thinking as we work to reposition the organization toward long-term value creation. This is an exciting and rapidly evolving space, and I encourage investors to conduct their own research into the total addressable market and emerging opportunities - we believe there's more potential here than most people realize." Early Restructuring Milestones Achieved in First Week Post-Transition: Since the leadership transition, BFCH has taken the following actions: Retired more than $2 million in legacy convertible debt through a fixed-price equity settlement Capped dilution through a $0.01 per share fixed-price conversion ceiling, with a 200 million share hard cap Reduced total liabilities to under $94,000 Submitted updated documentation to OTC Markets and initiated corporate rebranding to EVERMIND Holdings, Inc. As outlined in the business plan, the $0.01 per share threshold reflects a negotiated, fixed-price equity conversion designed to eliminate variable-rate dilution from legacy obligations. Beyond that, it serves as a structural benchmark - establishing a transparent, disciplined floor from which the Company intends to build. Management views this threshold not as a reflection of intrinsic value, but as a structural reference point aligned with the Company's current capital position and operating strategy. At an implied market cap of approximately $12 million, it establishes a consistent baseline from which future corporate activities - such as early-stage acquisitions or capital formation - may be planned and evaluated. Future equity activity will be structured in alignment with measurable execution milestones and long-term value creation. EVERMIND Holdings: Targeting Growth at the Intersection of Health, Technology, and Infrastructure The EVERMIND Holdings platform is designed to operate across three synergistic divisions - each targeting scalable, asset-backed opportunities in human optimization, cognitive performance, and longevity-focused innovation. EVERMIND Labs - Focused on acquiring, developing, and scaling consumer-facing wellness brands that address the rising demand for brain health, mood support, longevity, and performance enhancement. This division is expected to serve as the Company's primary revenue driver as the platform matures. EVERMIND Technologies - A future-focused division designed to identify, acquire, and incubate technologies at the intersection of brain performance, digital health, and longevity. This includes potential investments in neuro-assessment platforms, cognitive health apps, wearable devices, biometric feedback tools, and AI-driven performance analytics. The goal is to build a portfolio of scalable assets that complement EVERMIND's consumer and infrastructure strategy while enabling data-backed optimization across physical, cognitive, and biological domains. EVERMIND Manufacturing - A long-term strategic initiative to explore the development of domestic co-manufacturing infrastructure for functional consumer products. This division is designed to increase supply chain resilience, support internal brands, and serve third-party partners in the functional beverage, nutrition, and supplement categories. The business plan anticipates that each division may operate independently, contribute to overall platform growth, and, where appropriate, support future spin-off potential. Planned Capital Formation and Initial Asset Development To support the next phase of development, the Company is preparing to initiate a $150,000 seed round to fund near-term objectives, including: Completion of rebranding and regulatory filings Initiation of operational planning within EVERMIND Labs Legal and accounting infrastructure to support asset integration Design and buildout of corporate communications and investor relations strategy The Company is also evaluating a potential Regulation A offering, which may commence later in 2025, subject to share price, applicable filings, and qualifications. Any securities offerings will be conducted pursuant to available exemptions under federal and state securities laws. As of the date of this release, no definitive agreements for acquisitions have been signed. The Company is, however, in preliminary discussions regarding one or more potential transactions. Corporate Communications & Disclosure Infrastructure EVERMIND Holdings, Inc. is in the process of developing an updated FINRA-compliant corporate website featuring a dedicated investor relations section. All required documentation has been submitted to OTC Markets, and Company fees are paid in full. Once portal access is granted, BFCH will begin updating public disclosures and corporate information. A corporate communications plan is in development to ensure ongoing transparency and alignment with evolving investor expectations. In accordance with SEC guidance encouraging issuers to identify their official disclosure channels, BFCH advises investors and media that it uses the following platforms to share material information: Corporate Website: X / Twitter: OTC Markets Disclosure Portal: Press Releases and Public Conference Calls This list may be updated from time to time on the Company's website. ACCESS TO STRATEGIC BUSINESS PLAN The new business plan is available on a landing page for public viewing at: About BitFrontier Capital Holdings, Inc. (OTC: BFCH) BitFrontier Capital Holdings, Inc. (d/b/a EVERMIND Holdings, Inc.) is a Wyoming-based public company undergoing a strategic transformation under new leadership and ownership control. The Company is building a multi-division platform at the intersection of human optimization, cognitive performance, and longevity-focused innovation - with a focus on acquiring, incubating, and scaling high-impact assets in emerging wellness and performance categories. Led by its new CEO and controlling shareholder, Dr. Jordan P. Balencic, the Company is committed to executing a disciplined growth strategy while rebuilding trust and delivering long-term value to its shareholders. No assurances can be made regarding the timing or success of future developments. Forward-Looking Statements This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable laws. These statements are based on current management expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict. Forward-looking statements include, but are not limited to, statements about the Company's business strategy, potential acquisitions, planned capital raises, and other future events or performance. Actual results may differ materially due to factors such as market conditions, regulatory developments, and the Company's financial position. Readers are cautioned not to place undue reliance on these statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements except as required by law. Contact:Jordan P. Balencic, D.O.813-693-1377jbalencic@ View the original release on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-07-2025
- Business
- Yahoo
BioAdaptives Announces National Launch of NeuroRush™ — A Cutting-Edge Adaptogenic Nootropic for Mental Clarity, Focus, and Resilience
NeuroRush™ delivers a unique blend of adaptogens and nootropic herbs designed to enhance cognitive performance, stress response and long-term brain health, without dependency or burnout. LAS VEGAS, July 16, 2025 (GLOBE NEWSWIRE) -- BioAdaptives, Inc. (OTC: BDPT), an innovator in evidence-based wellness solutions, today announced the upcoming national release of NeuroRush™, a next-generation nootropic designed to support sustained cognitive performance, mental clarity, and stress adaptability. Following strong results in targeted test markets, NeuroRush™ is scheduled for full commercial release in August/September 2025. Developed as a premium adaptogen-based formula, NeuroRush™ combines six clinically studied ingredients—including Rhodiola Rosea, Ashwagandha, Bacopa Monnieri, Panax Ginseng, and Mucuna Pruriens—to deliver a balanced, non-jittery experience designed for high-functioning individuals. The product will be available in two formulations: one with natural caffeine for fast-acting mental energy, and a caffeine-free version for users sensitive to stimulants. 'We saw exceptional results in controlled launch markets,' said James Keener, CEO of BioAdaptives. 'Customers reported not only better focus and productivity, but also a noticeable improvement in mood, stress control, and cognitive stamina. NeuroRush™ represents our commitment to delivering plant-based performance solutions grounded in science.' NeuroRush™ is formulated to target multiple pathways involved in brain function and stress resilience, making it ideal for professionals, students, athletes, and older adults seeking enhanced mental performance without dependency or crash. The proprietary blend includes adaptogens, neurotransmitter precursors, and nootropic herbs that work synergistically to support dopamine balance, neuroplasticity, and mental endurance. BioAdaptives plans to distribute NeuroRush™ through select online retailers, direct-to-consumer channels, and strategic health & wellness partners nationwide. Initial consumer feedback has highlighted NeuroRush™ as a high-performance solution that stands apart from conventional stimulant-based brain products. About BioAdaptives, Inc. BioAdaptives, Inc. develops and markets science-based natural health and wellness products for both humans and animals. Its formulations leverage cutting-edge research in stem cell biology, adaptogens, and regenerative nutrition. The company's mission is to enhance the quality of life through innovation that works in harmony with the body's natural processes. For more information, visit: Contact:Emily HarrisonInvestor RelationsBioAdaptives, Inc.(702) 659-8829info@ Wire Service Contact:IBNAustin, OfficeEditor@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Malay Mail
02-07-2025
- Health
- Malay Mail
Struggling with math? Study shows a gentle electric jolt boosts arithmetic by up to 29pc — but only for some
WASHINGTON, July 2 — Struggle with math? A gentle jolt to the brain might help. A new study published yesterday in PLOS Biology suggests that mild electrical stimulation can boost arithmetic performance — and offers fresh insight into the brain mechanisms behind mathematical ability, along with a potential way to optimise learning. The findings could eventually help narrow cognitive gaps and help build a more intellectually equitable society, the authors argue. 'Different people have different brains, and their brains control a lot in their life,' said Roi Cohen Kadosh, a neuroscientist at the University of Surrey who led the research. 'We think about the environment — if you go to the right school, if you have the right teacher — but it's also our biology.' Cohen Kadosh and colleagues recruited 72 University of Oxford students, scanning their brains to measure connectivity between three key regions. Participants then tackled math problems that required either calculating answers or recalling memorised solutions. They found that stronger connections between the dorsolateral prefrontal cortex, which governs executive function, and the posterior parietal cortex, involved in memory, predicted better calculation performance. When the researchers applied a painless form of brain stimulation using electrode-fitted caps — a technique known as transcranial random noise stimulation — the low performers saw their scores jump by 25-29 per cent. The team believes the stimulation works by enhancing the excitability of neurons and interacting with GABA, a brain chemical that inhibits excessive activity — effectively compensating for weak neural connectivity in some participants. In fact, the stimulation helped underperformers reach or even surpass the scores of peers with naturally stronger brain wiring. But those who already performed well saw no benefit. 'Some people struggle with things, and if we can help their brain to fulfil their potential, we open them a lot of opportunities that otherwise would be closed,' said Cohen Kadosh, calling it an 'exciting time' for the field of brain stimulation research. Still, he flagged a key ethical concern: the risk that such technologies could become more available to those with financial means, widening — rather than closing — access gaps. He also urged the public not to try this at home. 'Some people struggle with learning, and if our research proves successful beyond the lab, we could help them fulfil their ambitions and unlock opportunities that might otherwise remain out of reach.' — AFP
Associated Press
06-06-2025
- Business
- Associated Press
PanBrain Technology, with EEG and tDCS Technologies, Wins Dual Honors in China
PanBrain Technology has been awarded as 'National High-tech Enterprise' and 'Specialized, Refined, Distinctive and Innovative' SME in Shenzhen 'Quality First, Technology Priority, Continuous Evolution, and User-Centric Innovation'— PanBrain Technology CA, UNITED STATES, June 6, 2025 / / -- PanBrain Technology Co., Ltd., a leading innovator in brain health technology, has been awarded the 2024 'National High-tech Enterprise' certification along with the 'Specialized, Refined, Distinctive and Innovative' Small and Medium Enterprise (SME) title in Shenzhen. These honors highlight the company's groundbreaking work in non-invasive brain-computer interface (BCI) technologies and strengthen its position in the global market. Driving Innovation in Non-Invasive Brain-Computer Interfaces Founded to revolutionize brain health, PanBrain Technology has dedicated itself to the development of advanced non-invasive BCI solutions. Its flagship product, the PanBrain Energy Capsule, combines sophisticated EEG monitoring with transcranial direct current stimulation (tDCS) to enhance cognitive performance, emotional regulation, and neuroplasticity. By targeting the prefrontal cortex, the device aims to restore neurotransmitter balance, thereby improving fluid intelligence and overall cognitive function. Recognition of Technological Excellence and Commercial Success The 'National High-tech Enterprise' certification underscores PanBrain Technology's robust research and development capabilities and successful commercialization of its innovations. This prestigious designation places the company among China's foremost technology enterprises, recognized for advancing scientific and technological frontiers. Commitment to Specialized Market Needs and Social Impact PanBrain Technology's distinction as a 'Specialized, Refined, Distinctive and Innovative' SME reflects its strategic focus on serving specific user groups, including the elderly, individuals with mood disorders, and those suffering from insomnia and anxiety. The company's tailored solutions, supported by rigorous scientific research, address these societal health challenges with user-friendly designs and innovative technology. Industry Recognition and Competition Success The PanBrain Energy Capsule has earned praise from users, healthcare professionals, and industry experts alike. The product was a finalist and received an Excellence Award at the 2024 China Shenzhen Innovation and Entrepreneurship Competition. Furthermore, PanBrain Technology was selected to represent Shenzhen in the finals of the 13th National Innovation and Entrepreneurship Competition, scheduled for Hangzhou in Q4 2024. Looking to the Future: Expanding Global Impact Committed to ongoing innovation, PanBrain Technology plans to advance its BCI technologies further, expand its product portfolio, and grow its global presence. The company continues to uphold its core values of 'Quality First, Technology Priority, Continuous Evolution, and User-Centric Innovation' as it strives to improve cognitive health and mental well-being worldwide. Panbrain PanBrain Technology [email protected] Visit us on social media: Facebook X LinkedIn Instagram YouTube Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
